Results 251 to 260 of about 32,878,841 (350)

A Personalized Therapeutic Approach for Liver Cancers Expressing the African-Centric P47S Variant of TP53. [PDF]

Mol Cancer Res
Foster M, Casey K, Cassel J, Ye Y, Diaz J, Shuda McGuire K, Barnoud T, Murphy ME.   +7 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Atypical Parathyroid Tumor: A Case Report on the Diagnostic and Therapeutic Approach. [PDF]

Cureus
Theofilopoulou S, Sidiropoulos T, Kokoropoulos P, Christodoulou S, Poulios E.   +4 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Combination of Palladium Nanoparticles and Tubastatin-A Potentiates Apoptosis in Human Breast Cancer Cells: A Novel Therapeutic Approach for Cancer [Retraction]. [PDF]

Int J Nanomedicine
europepmc   +1 more source

Adipose-Derived Stem Cells as Therapeutic Approach in Hypertrophic Scar Formation-A Systematic Review. [PDF]

Int Wound J
Kohlhauser M, Lüttschwager S, Pignet AL, Schellnegger M, Moshammer M, Kamolz LP.   +5 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis. [PDF]

Molecules
Sharon N, Ventura Y, Bernstein N, Gorelick J, Ben-Shabat S, Fleisher-Berkovich S.   +5 more
europepmc   +1 more source

Therapeutic approaches [PDF]

, 2005
openaire   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source